BCMA

Advertisement
Rebecca AraujoASCO 2021 | April 6, 2023
Teclistamab and talquetamab, two investigational bispecific antibodies, showed promising responses for the treatment of ...
Read More
Rebecca AraujoConference Coverage | March 31, 2023
Findings from the CARTITUDE clinical program found that ciltacabtagene autoleucel (cilta-cel), an anti-B cell maturation ...
Rebecca AraujoOncology | April 28, 2023
DocWire News spoke with Nikhil Munshi, MD, Professor at Harvard Medical School and medical oncologist at the Dana-Farber ...
Rebecca AraujoOncology | March 31, 2023
Pfizer Inc. has paused a clinical trial of a drug for multiple myeloma (MM) after several patients treated with the ...
Rebecca AraujoOncology | August 1, 2023
DocWire News sat down with Natalie Callander, MD, professor and director of the Myeloma Clinical Program at the ...
Kerri FitzgeraldOncology | April 10, 2023
Shaji Kumar, MD, consultant in the Division of Hematology and professor of medicine at Mayo Clinic Cancer Center in ...
Kerri FitzgeraldOncology | April 10, 2023
Shaji Kumar, MD, consultant in the Division of Hematology and professor of medicine at Mayo Clinic Cancer Center in ...
Kerri FitzgeraldOncology | April 10, 2023
Shaji Kumar, MD, consultant in the Division of Hematology and professor of medicine at Mayo Clinic Cancer Center in ...
Kerri FitzgeraldOncology | April 7, 2023
Belantamab mafodotin, an investigational anti-B-cell maturation antigen monoclonal antibody-drug conjugate, demonstrated ...
Kerri FitzgeraldOncology | April 6, 2023
A B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy resulted in a 100% response rate among ...
Kerri FitzgeraldOncology | August 28, 2023
A combination of humanized anti-CD19 and anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell ...
Advertisement
Advertisement
Latest News

April 30, 2025